Squarepoint
CLRB icon

Squarepoint’s Cellectar Biosciences CLRB Stock Holding History

Squarepoint’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,362
Closed -$117K – 4557
2025
Q1 		$117K Sell
12,362
-4,979
-29% -$45.1K ﹤0.01% 4182
2024
Q4 		$156K Buy
+17,341
New +$802K ﹤0.01% 4563
2024
Q2 		– Sell
-599
Closed -$71.5K – 4128
2024
Q1 		$71.5K Buy
+599
New +$64.9K ﹤0.01% 3840
2021
Q2 		– Sell
-456
Closed -$220K – 3279
2021
Q1 		$220K Buy
+456
New +$271K ﹤0.01% 2650
2020
Q4 		– Sell
-58
Closed -$22K – 2960
2020
Q3 		$22K Buy
58
+21
+57% +$8.29K ﹤0.01% 2413
2020
Q2 		$14K Buy
+37
New +$15.5K ﹤0.01% 2158

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $300M AUM 10.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Squarepoint's CLRB Position: Q2 2025 in Review

Squarepoint sold out of Cellectar Biosciences (CLRB) in Q2 2025, closing a stake of 12,362 shares — an estimated $117K sold.

Squarepoint first reported a position in CLRB in Q2 2020 and held it in 6 quarters. The position peaked at $220K in Q1 2021. 19 funds tracked by Wall St. Rank hold CLRB as of Q2 2025.

  • Squarepoint reported no remaining Cellectar Biosciences position as of Q2 2025 after selling out during the quarter.
  • Squarepoint sold 12,362 Cellectar Biosciences shares in Q2 2025, an estimated $117K.
  • Squarepoint first reported a position in Cellectar Biosciences in Q2 2020 and held it in 6 quarters.
  • Squarepoint's Cellectar Biosciences position peaked at $220K in Q1 2021.
  • 19 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2025.

Based on Squarepoint's 13F filing for Q2 2025, filed 14 Aug 2025.